MYX (ASX) MYX new all time highs, if and when possible?

Originally posted by Chartsshout ↑

Looks like bull is holding its fire after positioning itself above 90.
Waiting for numbers on 24th Aug 18.
Looks like if they are OK as expected
we go through one dollar then if not before.
If all keeps going well,
under that scenario MYX
may hit all time new highs by August 2019 end rather than my previous likely price projection of above 2 dollars by Dec 2019 end.
Here are few points from Feb 2018 presentation.
Have a good read to refresh yourself as a long term investor.

Some interesting reading from 1H 2018 FINNCL YR report.

23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE • Revenue of $243.3m, a decrease of 17% on 1HFY17 • Adjusted EBITDA of $70.2m, down 36% on 1HFY17 • Reported EBITDA of $23.0m, down 82% on 1HFY17 • Reported net loss after tax of $174.2m driven by asset impairments, abnormal Doryx® returns and stock obsolescence, restructuring expenses and restatement of deferred tax assets and liabilities following the US tax rate change • Positive operating cash flow of $48.0m • Significantly improved trading in 2QFY18 which has strengthened further into January • US generic market appears to be stabilising and competitor disruptions creating opportunities • Expanded Specialty Brands team to 120 sales representatives to drive growth of Fabior®, Sorilux® and Doryx® MPC • New Greenville manufacturing facility to commence production in the next month, enhancing internal capabilities and improving margins for third party transferred products • Business positioned for a stronger second half driven by stabilising generic market, new product launches, expanded dermatology sales team, contract services committed business pipeline and cost benefits from the restructure.

The pipeline is expected to drive growth in future periods driven by key launches including generic NuvaRing® and our patented formulation of SUBA®- Itraconazole as an anti-fungal in the United States.”

Summary of results1 Change on pcp $m 1HFY18 1HFY17 pcp $m % Revenue 243.3 294.8 (51.5) (17%) Gross profit 95.9 171.2 (75.3) (44%) GM% 39% 58% EBITDA – adjusted2 70.2 109.9 (39.7) (36%) EBITDA – reported 23.0 129.2 (106.2) (82%) Net income / (loss) - adjusted 16.0 59.5 (43.5) (73%) Net income / (loss) - reported (174.2) 72.7 (256.9) Nm

Adjusting for these one-off items, group revenue would have been down 13% on pcp, gross profit margin would have been 50% and adjusted EBITDA was $70.2m down 36%.

(Oh dear. These margins are higher than CSL)
What do you want to say here..

The Company remains committed to growing its core business segments by investing in both internal and external product development opportunities. During the half, the Company invested $63m in its facilities and product pipeline with $40m primarily spent on the expansion programs at Greenville and Salisbury, in addition to $23m on research and development. The solid oral dose manufacturing facility in Greenville is almost complete and the Company is in the process of transferring in house 8 acquired Teva products which are currently outsourced. This will increase the economic benefit that flows to Mayne Pharma as well as introduce downstream commercial manufacturing services to Metrics Contract Services

Expand

What will happen to MYX stock price when
MYX goes back to the index ASX 300 ASX 200. ETC.
Rememebr at the moment
MYX is a penny stock
and many fundies cant buy
it .
When when weightings of the index are redone
and MYX goes bcak to the index,
many fund managers are and will be
forced to buy MYX back.
We are heading fast towards discovery of fair price
of MYX stock it appears.

No.	Vol.	Price($)
1	2500	$4.02

No.

Vol.

Price($)

2500

$4.02

Price($)	Vol.	No.
$4.04	164	1

Price($)

Vol.

No.

$4.04

164

No.	Vol.	Price($)
1	2500	4.020
3	6375	4.010
9	17920	4.000
1	164	3.990
3	1415	3.980

No.

Vol.

Price($)

2500

4.020

6375

4.010

17920

4.000

164

3.990

1415

3.980

Price($)	Vol.	No.
4.040	164	1
4.050	164	1
4.060	164	1
4.070	164	1
4.080	164	1

Price($)

Vol.

No.

4.040

164

4.050

164

4.060

164

4.070

164

4.080

164

(20min delay)
Last $4.03		Change -0.190(4.50%)		Mkt cap ! $342.8M

Open	High	Low	Value	Volume
$4.10	$4.22	$4.02	$1.235M	303.3K

MYX new all time highs, if and when possible?, page-356

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Westgold sets its sights on top five producer status through merger with Karora

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MYX new all time highs, if and when possible?, page-356

Top Stories

Is oil undervalued?

GreenX picks up prospective copper project in Germany

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Westgold sets its sights on top five producer status through merger with Karora

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News